Log in
Sign up
Filgotinib

Filgotinib

An immunology drug developed by Galapagos and licensed to Gilead Sciences for the treatment of rheumatoid arthritis

OverviewStructured DataIssuesContributorsActivity
Contents

Filgotinib is an immunology drug developed by Galapagos and licensed to Gilead for the treatment of rheumatoid arthritis. Filgotinib has been evaluated in multiple late-stage clinical studies, demonstrating efficacy and safety. The drug is also being evaluated by Gilead for other autoimmune indications like Crohn’s disease, psoriatic arthritis and ulcerative colitis. Galapagos plans to have greater involvement in European commercialization of Filgotinib and split the development costs with Gilead.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Is a
Chemical substance
Chemical substance
Product
Product

Product attributes

Industry

Chemical Substance attributes

ChEMBL ID
CHEMBL3301607
CAS Registry Number
1206161-97-8
Canonical SMILES
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
DSSTox ID
DTXSID80152935
UNII
3XVL385Q0M

Other attributes

Wikidata ID
Q19904163

Find more entities like Filgotinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.